US equities |
MU $931.24 ▲+0.00% TSLA $362.44 ▲+0.00% AAPL $342.00 ▲+0.00% SPCX $148.62 ▲+0.00% NVDA $217.23 ▲+0.00% SNDK $1,394.83 ▲+0.00% SKHY $146.11 ▲+0.00% AMD $562.23 ▲+0.00%
FinancialContent

Articles published by enGene Holdings Inc.

News headline image
enGene Reports First Quarter 2026 Financial Results and Provides Business Update
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
News headline image
enGene to Participate in Upcoming Investor Conferences
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
News headline image
enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
News headline image
enGene Announces Expanded $125 Million Debt Facility with Hercules Capital, Inc.
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
News headline image
enGene Reports Full Year 2025 Financial Results and Provides Business Update
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
News headline image
enGene’s Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
News headline image
enGene to Present at the Piper Sandler 37th Annual Healthcare Conference
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
News headline image
enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded Warrants
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
News headline image
enGene Announces Proposed Public Offering of Common Shares
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
News headline image
Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 Months
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
News headline image
enGene to Host Conference Call to Provide Update on Pivotal Cohort of LEGEND Trial
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
News headline image
enGene to Participate in Upcoming Investor Conferences
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
News headline image
enGene Named a BioSpace 2026 Best Places to Work Winner
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
News headline image
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
News headline image
enGene Appoints Hussein Sweiti, M.D., MSc, as Chief Medical Officer
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
News headline image
enGene Reports Third Quarter 2025 Financial Results and Provides Business Update
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
News headline image
enGene Achieves Target Enrollment Milestone for LEGEND Trial Pivotal Cohort
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
News headline image
enGene to Participate in Upcoming Investor Conferences
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
News headline image
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
News headline image
enGene Announces Board and Leadership Appointments to Support Commercial Readiness
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
News headline image
FDA Grants RMAT Designation for enGene’s Detalimogene, Enabling Potential for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
News headline image
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
News headline image
enGene Reports Second Quarter 2025 Financial Results and Provides Business Update
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
News headline image
enGene Announces the Resignation of its Chief Medical Officer
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
News headline image
enGene to Present at the Jefferies Global Healthcare Conference
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
News headline image
enGene Names Amy Pott as Chief Global Commercialization Officer
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
News headline image
enGene to Participate in Upcoming Investor Conferences
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
News headline image
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
News headline image
enGene to Present at the Stifel 2025 Virtual Targeted Oncology Forum
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN
News headline image
enGene Reports First Quarter 2025 Financial Results and Provides Business Update
From enGene Holdings Inc.
Via Business Wire
Tickers ENGN